Bull Run
Home
Watchlist
Bull Run

India's AI-powered stock screener for NSE & BSE. 5,000+ stocks with fundamentals and real-time analysis.

info@bullrun.co.in

Navigate

  • Home
  • Smart Screener
  • Stock Battle Arena
  • Watchlist
  • Go Premium

Tools

  • Advanced Stock Screening
  • Stock Comparison Tool
  • Personal Watchlist
  • Ask AI Assistant
  • Browse All Stocks
  • IPO GMP Tracker
  • Market News & Blog

Indices

  • All Indices
  • Nifty 50 Stocks
  • Sensex Stocks
  • Nifty Bank
  • Nifty IT
  • Nifty Pharma
  • Nifty Midcap 100

Screeners

  • Top Dividend Stocks
  • Debt Free Stocks
  • Undervalued Stocks
  • High ROE Stocks
  • Low PE Stocks
  • Top Rated Stocks
  • Large Cap Stocks
  • Compare Stocks
  • Browse by Sector

Browse Stocks by Sector

View All →
Non Banking Financial Company (NBFC)PharmaceuticalsComputers - Software & ConsultingIndustrial ProductsCivil ConstructionAuto Components & EquipmentsSpecialty ChemicalsOther Financial ServicesIT Enabled ServicesPackagingHotels & ResortsCommodity ChemicalsOther Electrical EquipmentGarments & ApparelsPaper & Paper ProductsSoftware ProductsPackaged FoodsCement & Cement ProductsSugarHeavy Electrical EquipmentHospitalEdible OilPower GenerationHealthcare Service Provider
© 2026 Bull Run. All rights reserved.
AboutBlogPrivacy PolicyTerms of Service

Disclaimer: Ratings and scores are generated algorithmically from publicly available market data for educational and informational purposes only. They do not constitute investment advice or solicitation to buy/sell securities. Bull Run is not a SEBI-registered Research Analyst or Investment Adviser.

  1. Home
  2. /
  3. Sectors
  4. /
  5. Pharmaceuticals
  6. /
  7. Akums Drugs & Pharmaceuticals Ltd
Financial RatiosPE RatioShareholdingDividendQuarterly ResultsBalance SheetProfit & LossCash Flow

Akums Drugs & Pharmaceuticals Ltd Stock Price Today (NSE: AKUMS)

Akums Drugs & Pharmaceuticals Ltd

AKUMSPharmaceuticals
₹499.05+₹2.60 (+0.52%)↑
As on 21 Apr 2026, 11:00 am ISTMarket Closed

Fundamental Score

...

Akums Drugs & Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Akums Drugs & Pharmaceuticals Ltd share price today is ₹499.05, up +0.52% on NSE/BSE as of 21 April 2026. Akums Drugs & Pharmaceuticals Ltd (AKUMS) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹6.70K (Cr). The 52-week high for AKUMS share price is ₹622.95 and the 52-week low is ₹409.30. At a P/E ratio of 21.76x, AKUMS is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 17.19% and a debt-to-equity ratio of 0.03.

Akums Drugs & Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
₹0.00
Low
₹0.00
Volume
0
Change
+0.52%

Institutional Deep-Dive

Bull Run Research Hub

Live Price:₹499.05— Analysis below may reference an earlier price snapshot.

Akums Drugs & Pharmaceuticals Share Price: A ROCE-Driven Analysis

The pharmaceutical industry is experiencing a dynamic shift, with increasing pressure on companies to demonstrate efficient capital allocation alongside innovative drug development. Today's analysis examines the Akums Drugs & Pharmaceuticals share price, currently at ₹447.75, through the lens of Return on Capital Employed (ROCE). This analysis is part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, focusing on key financial metrics to assess the company's operational efficiency and competitive positioning.

Akums Drugs & Pharmaceuticals Ltd exhibits a Price-to-Earnings (PE) ratio of 21.76, which needs to be considered in light of its profitability. Crucially, the company boasts a ROCE of 16.2%. ROCE, a key indicator of how effectively a company generates profits from its capital, suggests a reasonable level of operational efficiency. This implies that for every ₹100 invested in the business, Akums generates ₹16.2 in earnings before interest and taxes. A higher ROCE generally indicates better profitability and capital management.

One crucial aspect to consider is how this 16.2% ROCE contributes to the company’s moat, or its sustainable competitive advantage. A consistently high ROCE, exceeding the cost of capital, can create a protective barrier against competitors. This allows Akums to reinvest profits at attractive rates, further strengthening its market position and potentially leading to higher valuations over time. However, sustaining this ROCE is key, as new entrants or changing market dynamics could erode this advantage. Comparing Akums' ROCE to its sector peers is essential to benchmark its performance. We can compare this to peers like Mankind Pharma Ltd, Smruthi Organics Ltd, and Balaxi Pharmaceuticals Ltd for a comprehensive peer study.

Moreover, while not explicitly measured by ROCE, management quality plays a vital role. Examining the operational effectiveness of Mankind Pharma Ltd provides further insight. Examining their strategic decision-making, supply chain management, and cost control measures can offer valuable insights into how Akums Drugs & Pharmaceuticals Ltd fares in terms of management quality relative to its competitors. While a strong ROCE indicates efficient capital utilization, sustained success requires effective leadership and strategic foresight. It is important to note that this analysis is purely observational and does not constitute financial advice.

SM
Analysis by Sweta Mishra
SEBI Registered Research Analyst

Akums Drugs & Pharmaceuticals Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
2 Apr 26₹490.00₹504.00₹479.55₹499.051.63L (Cr)
1 Apr 26₹473.90₹499.95₹473.90₹496.451.66L (Cr)
30 Mar 26₹467.10₹472.00₹458.40₹466.101.72L (Cr)
27 Mar 26₹492.10₹492.95₹470.10₹474.353.68L (Cr)
25 Mar 26₹478.80₹495.50₹478.80₹493.1553.34K (Cr)
24 Mar 26₹471.90₹482.00₹466.20₹477.701.23L (Cr)
23 Mar 26₹482.90₹483.00₹463.00₹467.401.09L (Cr)
20 Mar 26₹468.20₹487.65₹468.20₹483.401.24L (Cr)
19 Mar 26₹477.00₹477.00₹464.85₹468.2086.81K (Cr)
18 Mar 26₹463.00₹485.00₹463.00₹481.3093.84K (Cr)

Akums Drugs & Pharmaceuticals Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
Apr 2026₹473.90₹504.00₹473.90₹499.05+5.31%
Mar 2026₹472.00₹515.00₹456.55₹466.10-1.25%
Feb 2026₹445.00₹506.00₹424.20₹488.15+9.70%
Jan 2026₹453.40₹458.00₹409.30₹439.55-3.05%
Dec 2025₹425.95₹480.50₹414.00₹453.40+6.44%
Nov 2025₹463.95₹481.70₹411.40₹425.95-8.19%
Oct 2025₹441.50₹473.45₹437.00₹460.75+4.36%
Sept 2025₹456.00₹484.00₹438.05₹441.45-3.19%
Aug 2025₹520.00₹524.85₹452.20₹454.25-12.64%
Jul 2025₹588.50₹592.00₹511.70₹519.25-11.77%
Jun 2025₹572.00₹597.00₹532.60₹585.40+2.34%
May 2025₹519.35₹622.95₹498.00₹571.40+10.02%

AI Research Briefing

Powered by Gemini · 2026-04-17

CDMO play with EU optionality; execution is everything.

Research Confidence
6.0/10Moderate
OPERATOR-DRIVENConsolidation. 1M: -7.81%, 3M: -10.14%, 6M: -23.34%Fair. P/E of 21.76x vs. Industry P/E of 31.77x.

⚡WHAT'S HAPPENING NOW (last 2-4 weeks):

Akums Drugs shows bullish momentum with positive daily moving averages. The stock closed at ₹515.50 on April 13, 2026, a 4.84% increase from the previous close. ICICI Securities upgraded the stock to 'Hold' on April 10, 2026. FII holding increased to 1.38% in March 2026 from 1.14% in December 2025. Akums closed its trading window on April 1, 2026, in anticipation of FY26 results.

�� CORE STORY (THE REAL GAME):

Akums is being priced as a CDMO play, leveraging its manufacturing capabilities for regulated markets. The key is its ability to secure and execute long-term contracts with global pharma companies, shifting from generics to higher-margin formulations.

�� WHAT IS DRIVING THE STOCK:

CDMO Growth: Q3FY26 revenue grew 14.8% YoY, driven by CDMO and international formulations.

European Expansion: EUGMP certification for oral solid and liquid plants, with commercial supplies expected to commence in FY28, potentially generating EUR 35 million annually.

Zambia JV: Supplies for the Zambia JV (Akums holds 51%) are expected to begin soon, with a contract potentially fetching USD 25 million in annual revenue in CY26/27.

⚖️ BULL vs BEAR:

Bull:EUGMP certifications unlock high-margin regulated market access. Zambia JV adds incremental revenue stream. Strong CDMO growth continues, driven by volume traction and better capacity utilization.

Bear:Q2 PAT fell 35.8% due to muted CDMO growth and declining API prices. Small-cap, liquidity risk remains. Dependence on contract wins creates revenue concentration risk. Sharp EPS decline in the past 5 years (-42.93%).

�� WHAT MARKET IS PRICING:

The market is pricing in continued CDMO growth and successful expansion into regulated markets, specifically Europe. A failure to secure further contracts or delays in EU supply could trigger a correction.

�� BOTTOM LINE:

Akums is a CDMO story trading at 21.76x P/E, a discount to the industry, but execution risk is high. Any hiccup in European approvals or Zambia ramp-up will crush this stock.

Why Now
  • Bullish technical indicators signal upward price momentum
  • FIIs increased stake in Q4 FY26
  • EU GMP certifications received, paving the way for regulated market access
Potential Catalysts
  • New CDMO contract wins
  • Successful commencement of European supplies in FY28
  • Faster-than-expected ramp-up of Zambia JV
Key Risks
  • Small-cap, inherent liquidity risk
  • Q2 PAT decline raises concerns about CDMO growth sustainability
  • Revenue concentration risk from reliance on large contracts
Institutional Activity

FII increased stake from 1.14% to 1.38% in Q4 FY26

Macro Context

Indian pharma sector shifting towards backward integration and innovation.

Order Book / Expansion

Akums has a ₹1,760 Cr contract with a European pharma company for oral liquid formulations, with commercial supply expected from 2027.

Cash Flow Quality

Profit converting to cash. Free Cash Flow 5Y: ₹132.48 Cr

3–6 Month Outlook

Focus on executing existing contracts and securing new ones in regulated markets. European expansion is key to margin expansion over the next 2-3 years.

Primary Thesis Risk

Failure to execute on EU expansion will decimate the multiple.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Good

ROE

17.19%
Average

ROCE

16.20%
Poor

OPM (5Y)

5.62%

Div Yield

0.00%

Akums Drugs & Pharmaceuticals Ltd Valuation Check

Excellent

P/E Ratio

21.76x
Poor

Industry P/E

31.77x
Market-cap Classification
Mid-cap
Balance of growth potential and stability.

Market Cap

6.70K (Cr)

Shareholding Pattern

Excellent

Promoter

75.26%
Poor

FII

2.27%
Average

DII

9.28%
Excellent

Pledged

0.00%

Growth Engine

Poor

Profit Growth (Q)

-34.83%
Poor

Sales Growth (Q)

-1.51%
Good

Sales Growth (5Y)

11.27%
Poor

EPS Growth (5Y)

-42.93%
Excellent

Profit Growth (5Y)

48.93%

Balance Sheet Health

Excellent

Debt to Equity

0.03x
Excellent

Int. Coverage

6.61x

Free Cash Flow (5Y)

132.48 (Cr)

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Akums Drugs & Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of AKUMS across key market metrics for learning purposes.

Positive Indicators

8 factors identified

Strong Return on Equity (17.19%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (16.20%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Attractive Valuation (P/E: 21.76 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Strong Profit Growth Track Record (48.93% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.03)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (6.61x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Strong Cash Generation (₹132.48 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

3 factors identified

Profit Decline Concern (-34.83%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Weak Earnings Growth (-42.93% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Peer Comparison - Pharmaceuticals

Compare Akums Drugs & Pharmaceuticals Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Overall score
Valuation
Price metrics
Profitability
Return metrics
Financial Health
Debt management
Growth
5Y performance
Dividend
Yield %
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
Akums Drugs & Pharmaceuticals LtdAkums Drugs & P...Selected✓
AKUMS • 544222
46.1/100
₹499.05₹499
₹6697.10₹6697.10
21.76Average
21.8
Average
17.19%Good
17.19%
Good
16.20%Good
16.20%
Good
0.03Excellent
0.0
Excellent
48.93%Excellent
48.93%
Excellent
11.27%Good
11.27%
Good
0.00%
Sun Pharmaceutical Industries LtdSun Pharmaceuti...
SUNPHARMA • 524715
65.2/100
₹1668.60₹1669
₹433738.68₹433738.68
37.57Average
37.6
Average
16.86%Good
16.86%
Good
0.00%Poor
0.00%
Poor
0.07Excellent
0.1
Excellent
0.00%Average
0.00%
Average
0.00%Average
0.00%
Average
0.00%
Divis Laboratories LtdDivis Laborator...
DIVISLAB • 532488
67.9/100
₹6280.00₹6280
₹170445.88₹170445.88
68.59Average
68.6
Average
15.35%Good
15.35%
Good
0.00%Poor
0.00%
Poor
0.01Excellent
0.0
Excellent
0.00%Average
0.00%
Average
0.00%Average
0.00%
Average
0.00%
Torrent Pharmaceuticals LtdTorrent Pharmac...
TORNTPHARM • 500420
65.3/100
₹4191.20₹4191
₹126430.62₹126430.62
58.36Average
58.4
Average
26.52%Excellent
26.52%
Excellent
0.00%Poor
0.00%
Poor
0.33Excellent
0.3
Excellent
0.00%Average
0.00%
Average
0.00%Average
0.00%
Average
0.00%
Cipla LtdCipla Ltd...
CIPLA • 500087
59/100
₹1229.50₹1230
₹123059.76₹123059.76
22.62Average
22.6
Average
17.77%Good
17.77%
Good
0.00%Poor
0.00%
Poor
0.01Excellent
0.0
Excellent
0.00%Average
0.00%
Average
0.00%Average
0.00%
Average
0.00%
Dr Reddys Laboratories LtdDr Reddys Labor...
DRREDDY • 500124
59.2/100
₹1237.80₹1238
₹105224.96₹105224.96
18.23Average
18.2
Average
17.96%Good
17.96%
Good
0.00%Poor
0.00%
Poor
0.16Excellent
0.2
Excellent
0.00%Average
0.00%
Average
0.00%Average
0.00%
Average
0.00%
Lupin LtdLupin Ltd...
LUPIN • 500257
66.7/100
₹2328.70₹2329
₹95148.15₹95148.15
22.00Average
22.0
Average
20.62%Excellent
20.62%
Excellent
0.00%Poor
0.00%
Poor
0.32Excellent
0.3
Excellent
0.00%Average
0.00%
Average
0.00%Average
0.00%
Average
0.00%
Zydus Lifesciences LtdZydus Lifescien...
ZYDUSLIFE • 532321
68.7/100
₹936.50₹937
₹94253.78₹94253.78
18.74Average
18.7
Average
21.21%Excellent
21.21%
Excellent
0.00%Poor
0.00%
Poor
0.38Excellent
0.4
Excellent
0.00%Average
0.00%
Average
0.00%Average
0.00%
Average
0.00%
Mankind Pharma LtdMankind Pharma ...
MANKIND • 543904
50.6/100
₹2144.00₹2144
₹92012.53₹92012.53
52.62Average
52.6
Average
14.68%Average
14.68%
Average
0.00%Poor
0.00%
Poor
0.55Good
0.6
Good
0.00%Average
0.00%
Average
0.00%Average
0.00%
Average
0.00%
Aurobindo Pharma LtdAurobindo Pharm...
AUROPHARMA • 524804
28.8/100
₹1367.80₹1368
₹70798.69₹70798.69
20.69Average
20.7
Average
11.08%Average
11.08%
Average
0.00%Poor
0.00%
Poor
0.22Excellent
0.2
Excellent
0.00%Average
0.00%
Average
0.00%Average
0.00%
Average
0.00%
Alkem Laboratories LtdAlkem Laborator...
ALKEM • 539523
59.5/100
₹5642.00₹5642
₹67075.29₹67075.29
28.54Average
28.5
Average
19.39%Good
19.39%
Good
0.00%Poor
0.00%
Poor
0.18Excellent
0.2
Excellent
0.00%Average
0.00%
Average
0.00%Average
0.00%
Average
0.00%

Akums Drugs & Pharmaceuticals Ltd Financial Statements

Comprehensive financial data for Akums Drugs & Pharmaceuticals Ltd including income statement, balance sheet and cash flow

About AKUMS (Akums Drugs & Pharmaceuticals Ltd)

Akums Drugs & Pharmaceuticals Ltd. is a powerhouse within the Indian pharmaceutical landscape, standing as a comprehensive contract development and manufacturing organization (CDMO...). They function as a vital hub, orchestrating the production of a vast portfolio of pharmaceutical and healthcare solutions, spanning from essential medications to sophisticated formulations. The company's expertise extends across diverse therapeutic areas, catering to both acute and chronic conditions with unwavering commitment to quality and innovation. With a strong foothold in the domestic market, Akums also strategically projects its reach globally, solidifying its position as a reliable partner for pharmaceutical companies seeking manufacturing excellence. This unwavering dedication has positioned Akums as a significant contributor to the healthcare industry, enabling the provision of affordable and quality healthcare solutions for diverse demographics. Beyond conventional pharmaceuticals, Akums embraces a holistic approach to well-being, demonstrated by its involvement in the production of ayurvedic medicines, herbal remedies, and nutraceuticals. This reflects an awareness of the growing consumer demand for natural and alternative therapies, with production conducted under rigorous regulatory standards and quality controls. The company's comprehensive product range further incorporates toiletries, derma and cosmetic products, and food supplements, showcasing its diversification and commitment to addressing various aspects of health and personal care. Akums is dedicated to continuously refining its processes and technologies, ensuring the delivery of products that align with the evolving needs of the healthcare industry. Akums Drugs & Pharmaceuticals Ltd. operates a network of state-of-the-art manufacturing facilities adhering to stringent international quality standards, including certifications from WHO-GMP and other reputed regulatory bodies. This infrastructural strength enables the company to deliver a wide range of dosage forms, including tablets, capsules, liquids, injectables, and topical preparations. Moreover, the company offers a comprehensive suite of services encompassing formulation development, analytical testing, and stability studies, positioning it as a complete solution provider for pharmaceutical companies. By fostering collaborations and partnerships, Akums aims to drive advancements in healthcare, enabling access to quality and affordable medicines for populations worldwide.

Company Details

Symbol:AKUMS
Industry:Pharmaceuticals
Sector:Pharmaceuticals
Website:https://www.akums.in

Key Leadership

Mr. Sanjeev Jain
Co-Founder, MD & Whole Time Director
Mr. Sandeep Jain
Co Founder, MD & Director
Mr. Sumeet Sood
Chief Financial Officer

Latest News

Akums Drugs share price cracks 7% following IT Department search. Details here - livemint.com
livemint.com• 1/22/2025
Akums Drugs bags ₹1,760 cr deal with European pharma; stock jumps 5% - Fortune India
Fortune India• 12/24/2024
Akums Drugs and Pharmaceuticals Limited’s Initial Public Offer to open on July 30, 2024 - APN News
APN News• 7/26/2024

AKUMS Share Price: Frequently Asked Questions

What is the current share price of Akums Drugs & Pharmaceuticals Ltd?

As of 21 Apr 2026, 11:00 am IST, Akums Drugs & Pharmaceuticals Ltd share price is ₹499.05. The Akums Drugs & Pharmaceuticals Ltd stock has a market capitalisation of ₹6.70K (Cr) on NSE/BSE.

Is Akums Drugs & Pharmaceuticals Ltd share price Overvalued or Undervalued?

Akums Drugs & Pharmaceuticals Ltd share price is currently trading at a P/E ratio of 21.76x, compared to the industry average of 31.77x. Based on this relative valuation, the Akums Drugs & Pharmaceuticals Ltd stock appears to be Undervalued against its sector peers.

What is the 52-week high and low of Akums Drugs & Pharmaceuticals Ltd share price?

The 52-week high of Akums Drugs & Pharmaceuticals Ltd share price is ₹622.95 and the 52-week low is ₹409.30. These values are updated daily from NSE/BSE price data.

What factors affect the Akums Drugs & Pharmaceuticals Ltd share price?

Key factors influencing Akums Drugs & Pharmaceuticals Ltd share price include quarterly earnings growth (Sales Growth: -1.51%), raw material costs, government spending, and institutional flows (FII/DII holding).

Is Akums Drugs & Pharmaceuticals Ltd a good stock for long-term investment?

Akums Drugs & Pharmaceuticals Ltd shows a 5-year Profit Growth of 48.93% and an ROE of 17.19%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.03 before investing in Akums Drugs & Pharmaceuticals Ltd shares.

How does Akums Drugs & Pharmaceuticals Ltd compare with its industry peers?

Akums Drugs & Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare Akums Drugs & Pharmaceuticals Ltd share price P/E of 21.76x and ROE of 17.19% against the industry averages to determine competitive standing.

What is the P/E ratio of Akums Drugs & Pharmaceuticals Ltd and what does it mean?

Akums Drugs & Pharmaceuticals Ltd share price has a P/E ratio of 21.76x compared to the industry average of 31.77x. Investors pay ₹22 for every ₹1 of annual earnings.

How is Akums Drugs & Pharmaceuticals Ltd performing according to Bull Run's analysis?

Akums Drugs & Pharmaceuticals Ltd has a Bull Run fundamental score of 46.1/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.

What sector and industry does Akums Drugs & Pharmaceuticals Ltd belong to?

Akums Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Akums Drugs & Pharmaceuticals Ltd share price.

What is Return on Equity (ROE) and why is it important for AKUMS?

AKUMS has an ROE of 17.19%, which indicates excellent management efficiency. ROE measures how efficiently Akums Drugs & Pharmaceuticals Ltd generates profits from shareholders capital.

How is AKUMS debt-to-equity ratio and what does it indicate?

AKUMS has a debt-to-equity ratio of 0.03, which indicates conservative financing with low financial risk.

What is AKUMS dividend yield and is it a good dividend stock?

AKUMS offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Akums Drugs & Pharmaceuticals Ltd shares.

How has AKUMS share price grown over the past 5 years?

AKUMS has achieved 5-year growth rates of: Sales Growth 11.27%, Profit Growth 48.93%, and EPS Growth -42.93%.

What is the promoter holding in AKUMS and why does it matter?

Promoters hold 75.26% of AKUMS shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Akums Drugs & Pharmaceuticals Ltd.

What is AKUMS market capitalisation category?

AKUMS has a market capitalisation of ₹6697 crores, placing it in the Mid-cap category.

How volatile is AKUMS stock?

AKUMS has a beta of N/A. A beta > 1 suggests the Akums Drugs & Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is AKUMS operating profit margin trend?

AKUMS has a 5-year average Operating Profit Margin (OPM) of 5.62%, indicating the company's operational efficiency.

How is AKUMS quarterly performance?

Recent quarterly performance shows Akums Drugs & Pharmaceuticals Ltd YoY Sales Growth of -1.51% and YoY Profit Growth of -34.83%.

What is the institutional holding pattern in AKUMS?

AKUMS has FII holding of 2.27% and DII holding of 9.28%. Significant institutional holding often suggests professional confidence in the Akums Drugs & Pharmaceuticals Ltd stock.

HomeScreenerBattleWatchlist